Hoffman R, Bruno E, Elwell J, Mazur E, Gewirtz A M, Dekker P, Denes A E
Blood. 1982 Nov;60(5):1173-8.
The possible pathogenetic mechanisms responsible for the production of acquired amegakaryocytic thrombocytopenic purpura (AATP) were investigated in a group of patients with this disorder. Absence of megakaryocytes and small platelet glycoprotein-bearing mononuclear cells, as determined by immunochemical staining of patient marrows with an antisera to platelet glycoproteins, suggested that the defect in AATP occurs in an early progenitor cell of the megakaryocytic lineage. Using an in vitro clonal assay system for negakaryocytic progenitor cells or megakaryocyte colony-forming units (CFU-M), the proliferative capacity of AATP marrow cells was then assessed. Bone marrow cells from three of four patients formed virtually no megakaryocyte colonies, suggesting that in these individuals the AATP was due to an intrinsic defect in the CFU-M. Bone marrow cells from an additional patient, however, formed 12% of the normal numbers of colonies, providing evidence for at least partial integrity of the CFU-M compartment in this patient. Serum specimens from all six patients were screened for their capacity to alter in vitro megakaryocyte colony formation. Five of six sera enhanced colony formation in a stepwise fashion, demonstrating appropriately elevated levels of megakaryocyte colony-stimulating activity. The serum of the patient with partial integrity of the CFU-M compartment, however, stimulated colony formation only at low concentrations. At higher concentrations, this patient's serum actually inhibited the number of colonies cloned, suggesting the presence of a humoral inhibitor to CFU-M. Serum samples from all patients were further screened for such humoral inhibitors of megakaryocyte colony formation using a cytotoxicity assay. The patient whose serum was inhibitory to CFU-M at high concentrations was indeed found to have a complement-dependent serum IgG inhibitor that was cytotoxic to allogeneic and autologous marrow CFU-M but did not alter erythroid colony formation. These-studies suggest that AATP can be due to at least two mechanisms: either an intrinsic effect at the level of the CFU-M or a circulating cytotoxic autoantibody directed against the CFU-M.
我们对一组获得性无巨核细胞性血小板减少性紫癜(AATP)患者的发病机制进行了研究。通过用抗血小板糖蛋白抗血清对患者骨髓进行免疫化学染色,发现缺乏巨核细胞和含血小板糖蛋白的小单核细胞,这表明AATP的缺陷发生在巨核细胞系的早期祖细胞中。然后,我们使用巨核细胞祖细胞或巨核细胞集落形成单位(CFU-M)的体外克隆检测系统,评估了AATP骨髓细胞的增殖能力。四名患者中有三名患者的骨髓细胞几乎没有形成巨核细胞集落,这表明在这些个体中,AATP是由于CFU-M的内在缺陷所致。然而,另一名患者的骨髓细胞形成的集落数量为正常数量的12%,这为该患者CFU-M区室至少部分完整提供了证据。我们对所有六名患者的血清标本进行了筛选,以检测其改变体外巨核细胞集落形成的能力。六份血清中有五份以逐步方式增强了集落形成,表明巨核细胞集落刺激活性水平适当升高。然而,CFU-M区室部分完整的患者的血清仅在低浓度下刺激集落形成。在较高浓度下,该患者的血清实际上抑制了克隆的集落数量,这表明存在一种针对CFU-M的体液抑制剂。我们使用细胞毒性试验对所有患者的血清样本进一步筛选了这种巨核细胞集落形成的体液抑制剂。确实发现,其血清在高浓度下对CFU-M有抑制作用的患者有一种补体依赖性血清IgG抑制剂,该抑制剂对同种异体和自体骨髓CFU-M具有细胞毒性,但不会改变红系集落形成。这些研究表明,AATP可能至少由两种机制引起:要么是CFU-M水平的内在效应,要么是针对CFU-M的循环细胞毒性自身抗体。